Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label randomized trial of Ninjin'yoeito in COPD patients with fatigue
jRCTs031210583Completed
- Sponsor
- Kracie Pharmaceutical
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of ninjinyoeito in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Kracie Pharmaceutical. Primary endpoints: Fatigue (VAS), Walking speed and 1 more. Started Mar 2022; status: completed.
02
Drugs
ninjinyoeito
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on jRCTs031210583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210583.